PAFAH2

Summary

Gene Symbol: PAFAH2
Description: platelet activating factor acetylhydrolase 2
Alias: HSD-PLA2, platelet-activating factor acetylhydrolase 2, cytoplasmic, SD-PLA2, platelet-activating factor acetylhydrolase 2, 40kDa, serine-dependent phospholipase A2
Species: human
Products:     PAFAH2

Top Publications

  1. Rice S, Southan C, Boyd H, Terrett J, Macphee C, Moores K, et al. Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem J. 1998;330 ( Pt 3):1309-15 pubmed
    Using expressed sequence tag (EST) homology screening, a new human serine dependent phospholipase A2 (HSD-PLA2) was identified that has 40% amino acid identity with human low density lipoprotein-associated phospholipase A2 (LDL-PLA2)...
  2. Min J, Wilder C, Aoki J, Arai H, Inoue K, Paul L, et al. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry. 2001;40:4539-49 pubmed
  3. Hattori K, Adachi H, Matsuzawa A, Yamamoto K, Tsujimoto M, Aoki J, et al. cDNA cloning and expression of intracellular platelet-activating factor (PAF) acetylhydrolase II. Its homology with plasma PAF acetylhydrolase. J Biol Chem. 1996;271:33032-8 pubmed
  4. Marques M, Pei Y, Southall M, Johnston J, Arai H, Aoki J, et al. Identification of platelet-activating factor acetylhydrolase II in human skin. J Invest Dermatol. 2002;119:913-9 pubmed
  5. Schmidt E, Koenig W, Khuseyinova N, Christensen J. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008;196:420-4 pubmed
    ..The results support the view that Lp-PLA(2) may relate to CAD and that intake of marine n-3 fatty acids might reduce plasma Lp-PLA(2) suggesting another mechanism by which n-3 fatty acids could reduce the risk of cardiovascular disease. ..
  6. Monillas E, Caplan J, Thévenin A, Bahnson B. Oligomeric state regulated trafficking of human platelet-activating factor acetylhydrolase type-II. Biochim Biophys Acta. 2015;1854:469-75 pubmed publisher
    ..It is hypothesized that the balance between monomer and dimer serves as a regulatory mechanism of a PAFAH-II oxidative stress response. ..
  7. Moschos M, Pantazis P, Gatzioufas Z, Panos G, Gazouli M, Nitoda E, et al. "Association between platelet activating factor acetylhydrolase and diabetic retinopathy: Does inflammation affect the retinal status?". Prostaglandins Other Lipid Mediat. 2016;122:69-72 pubmed publisher
    ..114 μmol/min/ml, post-hoc Bonferroni comparison test: p<0.0001) and to NPDR group (0.147 μmol/min/ml, post-hoc Bonferroni comparison test: p=0.012). The activity of PAF-AH in the plasma increases in parallel with DR severity. ..
  8. Stafforini D, McIntyre T, Zimmerman G, Prescott S. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895-8 pubmed
  9. Unno N, Sakaguchi T, Nakamura T, Yamamoto N, Sugatani J, Miwa M, et al. A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease. J Surg Res. 2006;134:36-43 pubmed
    ..5 (6.0-40.3) compared with normal genotype and normal lipid level. The plasma PAF-AH gene polymorphism and hypercholesterolemia may interact and increase the risk of atherosclerosis. ..
  10. Umemura K, Kato I, Hirashima Y, Ishii Y, Inoue T, Aoki J, et al. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke. 2007;38:1063-8 pubmed
    ..1+/-16.9%; hippocampus, 58.9+/-15.3%). These results indicate that PAF-AH II exerts strong neuroprotective effects against ischemic injury and suggest a possibility for clinical use of this enzyme in cerebral ischemia. ..

Detail Information

Publications10

  1. Rice S, Southan C, Boyd H, Terrett J, Macphee C, Moores K, et al. Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem J. 1998;330 ( Pt 3):1309-15 pubmed
    Using expressed sequence tag (EST) homology screening, a new human serine dependent phospholipase A2 (HSD-PLA2) was identified that has 40% amino acid identity with human low density lipoprotein-associated phospholipase A2 (LDL-PLA2)...
  2. Min J, Wilder C, Aoki J, Arai H, Inoue K, Paul L, et al. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry. 2001;40:4539-49 pubmed
  3. Hattori K, Adachi H, Matsuzawa A, Yamamoto K, Tsujimoto M, Aoki J, et al. cDNA cloning and expression of intracellular platelet-activating factor (PAF) acetylhydrolase II. Its homology with plasma PAF acetylhydrolase. J Biol Chem. 1996;271:33032-8 pubmed
  4. Marques M, Pei Y, Southall M, Johnston J, Arai H, Aoki J, et al. Identification of platelet-activating factor acetylhydrolase II in human skin. J Invest Dermatol. 2002;119:913-9 pubmed
  5. Schmidt E, Koenig W, Khuseyinova N, Christensen J. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008;196:420-4 pubmed
    ..The results support the view that Lp-PLA(2) may relate to CAD and that intake of marine n-3 fatty acids might reduce plasma Lp-PLA(2) suggesting another mechanism by which n-3 fatty acids could reduce the risk of cardiovascular disease. ..
  6. Monillas E, Caplan J, Thévenin A, Bahnson B. Oligomeric state regulated trafficking of human platelet-activating factor acetylhydrolase type-II. Biochim Biophys Acta. 2015;1854:469-75 pubmed publisher
    ..It is hypothesized that the balance between monomer and dimer serves as a regulatory mechanism of a PAFAH-II oxidative stress response. ..
  7. Moschos M, Pantazis P, Gatzioufas Z, Panos G, Gazouli M, Nitoda E, et al. "Association between platelet activating factor acetylhydrolase and diabetic retinopathy: Does inflammation affect the retinal status?". Prostaglandins Other Lipid Mediat. 2016;122:69-72 pubmed publisher
    ..114 μmol/min/ml, post-hoc Bonferroni comparison test: p<0.0001) and to NPDR group (0.147 μmol/min/ml, post-hoc Bonferroni comparison test: p=0.012). The activity of PAF-AH in the plasma increases in parallel with DR severity. ..
  8. Stafforini D, McIntyre T, Zimmerman G, Prescott S. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895-8 pubmed
  9. Unno N, Sakaguchi T, Nakamura T, Yamamoto N, Sugatani J, Miwa M, et al. A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease. J Surg Res. 2006;134:36-43 pubmed
    ..5 (6.0-40.3) compared with normal genotype and normal lipid level. The plasma PAF-AH gene polymorphism and hypercholesterolemia may interact and increase the risk of atherosclerosis. ..
  10. Umemura K, Kato I, Hirashima Y, Ishii Y, Inoue T, Aoki J, et al. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke. 2007;38:1063-8 pubmed
    ..1+/-16.9%; hippocampus, 58.9+/-15.3%). These results indicate that PAF-AH II exerts strong neuroprotective effects against ischemic injury and suggest a possibility for clinical use of this enzyme in cerebral ischemia. ..